MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Mirati Therapeutics Inc

Fermé

SecteurSoins de santé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-0.05% downside

Sentiment de l'Actualité

By Acuity

50%

50%

154 / 376 Classement par Healthcare

Mirati Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 juil. 2025, 21:01 UTC

Résultats

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

18 juil. 2025, 20:46 UTC

Résultats

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 juil. 2025, 20:39 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 juil. 2025, 20:36 UTC

Résultats

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 juil. 2025, 20:16 UTC

Acquisitions, Fusions, Rachats

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 juil. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 juil. 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 juil. 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 juil. 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 juil. 2025, 18:24 UTC

Résultats

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 juil. 2025, 18:19 UTC

Résultats

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 juil. 2025, 18:11 UTC

Acquisitions, Fusions, Rachats

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 juil. 2025, 18:11 UTC

Résultats

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 juil. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 juil. 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 juil. 2025, 16:28 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 juil. 2025, 16:22 UTC

Résultats

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Energy & Utilities Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

18 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 juil. 2025, 16:04 UTC

Résultats

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 juil. 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 juil. 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 juil. 2025, 15:47 UTC

Market Talk
Résultats

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparaison

Variation de prix

Mirati Therapeutics Inc prévision

Objectif de Prix

By TipRanks

-0.05% baisse

Prévisions sur 12 Mois

Moyen 58.67 USD  -0.05%

Haut 59 USD

Bas 58 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

0

Achat

5

Maintien

0

Vente

Sentiment

By Acuity

154 / 376Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

$

À Propos Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.